A critical review of perfluorooctanoate and perfluorooctanesulfonate exposure and cancer risk in humans

Critical Reviews in Toxicology

Volumn 44, Issue S1, 2014, Pages 1-81

  Chang, Ellen T ^a   Adami, Hans Olov ^b   Boffetta, Paolo ^c   Cole, Philip ^d   Starr, Thomas B ^e   Mandel, Jack S ^a  

^a EXPONENT INC   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e TBS Associates   (United States)

Author keywords

Ammonium perfluorooctanoate; Cancer; Epidemiology; Humans; Perfluoroalkyl substances; Perfluorooctanesulfonate; Perfluorooctanesulfonyl fluoride; Perfluorooctanoate

Indexed keywords

PERFLUOROOCTANESULFONIC ACID; PERFLUOROOCTANOIC ACID; ALKANESULFONIC ACID; FLUOROCARBON; OCTANOIC ACID DERIVATIVE;

CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CARCINOGENESIS; CARCINOGENICITY; DISEASE ASSOCIATION; ENVIRONMENTAL EXPOSURE; EUROPE; EXPERIMENTAL RAT; HEALTH CARE FACILITY; HUMAN; KIDNEY CANCER; LIVER CANCER; NEOPLASM; NONHUMAN; OCCUPATIONAL EXPOSURE; PANCREAS CANCER; POPULATION EXPOSURE; PROSTATE CANCER; REVIEW; SYSTEMATIC REVIEW; TESTIS CANCER; THYROID CANCER; UNITED STATES; WORKER; ADVERSE EFFECTS; ANIMAL; NEOPLASMS; PATHOLOGY; RISK;

ALKANESULFONIC ACIDS; ANIMALS; CAPRYLATES; ENVIRONMENTAL EXPOSURE; FLUOROCARBONS; HUMANS; NEOPLASMS; OCCUPATIONAL EXPOSURE; RISK;

EID: 84900431692     PISSN: 10408444     EISSN: 15476898     Source Type: Journal    
DOI: 10.3109/10408444.2014.905767     Document Type: Review

References (87)

1. 3M Company. (2013). 3M's Phase Out and New Technologies. Available at: http://www.solutions.3m.com/wps/portal/3M/en-US/PFOS/PFOA/Information/ phase-out-technologies/. Last accessed: 09/25/2013.
2. Adami HO Berry SC Breckenridge CB Smith LL Swenberg JA Trichopoulos D et al. (2011). Toxicology and epidemiology: improving the science with a framework for combining toxicologic al and epidemiological evidence to establish causal inference. Toxicol Sci 122 223-34 .
3. Alexander BH Olsen GW Burris JM Mandel JH Mandel JS. (2003). Mortality of employees of a perfl uoroo ctanesulphonyl fl uoride manufacturing facility. Occup Environ Med 60 722-9 .
4. Alexander BH Olsen GW. (2007). Bladder cancer in perfl uorooctanesulfonyl fl uoride manufacturing workers. Ann Epidemiol 17 471-8.
5. Andersen ME Clewell III H.J. Tan YM Butenhoff JL Olsen GW. (2006). Pharmacokinetic modeling of saturable renal resorption of perfl uoroalkylacids in monkeys-probing the determinan ts of long plasma half-lives. Toxicology 227 156-64 .
6. Andersen ME Preston RJ Maier A Willis AM Patterson J. (2014). Dose-response approaches for nuclear receptor-mediated modes of action for l iver carcinogenicity: results of a workshop. Crit Rev Toxicol 44 50-63 .
7. Barry V Winquist A Steenland K. (2013). Perfl uorooctanoic Acid (PFOA) exposures and incident cancers among adults living near a chem ical plant. Environ Health Perspect 121 1313-18 .
8. Biegel LB Hurtt ME Frame SR O'Connor JC Cook JC. (2001). Mechanisms of extrahepatic tumor induction by peroxisome proliferators in male CD rats. Toxicol Sci 60 44-55.
9. Bonefeld-Jorgensen EC Long M Bossi R Ayotte P Asmund G Kruger T et al. (2011). Perfl uorinated compounds are related to breast cancer risk in Greenlandic I nuit: A case control study. Environ Health 10 88 .
10. Buck RC Franklin J Berger U Conder JM Cousins IT de Voogt P et al. (2011). Perfl uoroalkyl and polyfl uoroalkyl substances in the environment: terminology classifi cation and origins. Integr Environ Assess Manag 7 513-41 .
11. Budinsky RA Schrenk D Simon T Van den Berg M Reichard JF Silkworth JB et al. (2014). Mo de of action and dose-response framework analysis for receptor-mediated toxicity: the aryl hydrocarbon receptor as a case study. Crit Rev Toxicol 44 83-119.
12. Butenhoff JL Chang SC Olsen GW Thomford PJ. (2012 b). Chronic dietary toxicity and carcinogenicity study with potassium perfl uorooctanesulfonate in Sprague Dawley rats. Toxicology 293 1-15 .
13. Butenhoff JL Kennedy GL Jr Chang SC Olsen GW. (2012 a). Chronic dietary toxicity and carcinogenicity study with ammonium perfl uorooctanoate in Sprague-Dawley rats. Toxicology 298 1-13.
14. Bute nhoff JL Olsen GW Pfahles-Hutchens A. (2006). The applicability of biomonitoring data for perfl uorooctanesulfonate to the environmental public health continuum. Environ Health Perspect 114 1776-82 .
15. Calafat AM Kuklenyik Z Reidy JA Caudill SP Tully JS Needham LL. (2007). Serum concentrations of 11 polyfl uoroalkyl compounds in the U.S. population: data from the National Health and Nutrition Examination Surve y (NHANES). Environ Sci Technol 41 2237-42.
16. Chang SC Noker PE Gorman GS Gibson SJ Hart JA Ehresman DJ Butenhoff JL. (2012). Comparative pharmacokinetics of perfl uorooctanesulfonate (PFOS) in rats mice and monkeys. Reprod Toxicol 33 428-40 .
17. Consonni D Straif K Symons JM Tomenson JA van Amelsvoort LG Sleeuwenhoek A et al. (2013). Cancer risk among tetrafl uo roethylene synthesis and polymerization workers. Am J Epidemiol 178 350-8 .
18. Cook JC Murray SM Frame SR Hurtt ME. (1992). Induction of Leydig cell adenomas by ammonium perfl uorooctanoate: A pos sible endocrinerelated mechanism. Toxicol Appl Pharmacol 113 209-17 .
19. Corton JC Cunningham ML Hummer BT Lau C Meek B Peters JM et al. (2014). Mode of action framework analysis f or receptormediated toxicity: the peroxisome proliferator-activated receptor alpha (PPARalpha) as a case study. Crit Rev Toxicol 44 1-49 .
20. Cote S Ayotte P Dodin S Blanchet C Mulvad G Petersen H S et al. (2006). Plasma organochlorine concentrations and bone ultrasound measurements: A cross-sectional study in peri-and postmenopausal Inuit women from Greenland. Environ Health 5 33 .
21. Deutch B Pedersen HS Asmund G Hansen JC. (2007). Contaminants diet plasma fatty acids and smoking in Greenland 1999-2005. Sci Total Environ 372 486-96 .
22. Elcombe CR Elcombe BM Foster JR Chan g SC Ehresman DJ Butenhoff JL. (2012). Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats from dietary exposure to potassium perfl uorooctanesulfonate results from increased expression of xenosensor nuclear receptors PPARalpha and CAR/PXR. Toxicology 293 16-29 .
23. Elcombe CR Elcombe BM Foster JR Farrar DG Jung R Chang SC et al. (2010). Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats following dietary exposure to ammonium perfl uorooctanoate occurs through increased activation of the xenosensor nuclear receptors PPARalpha and CAR/PXR. Arch Toxicol 84 787-98 .
24. Elcombe CR Peff er RC Wolf DC Bailey J Bars R Bell D et al. (2014). Mode of action and human relevance analysis for nuclear receptormediated liver toxicity: A case study with phenobarbital as a model constitutive androstane receptor (CAR) activator. Crit Rev Toxic ol 44 64-82 .
25. Eriksen KT Sorensen M McLaughlin JK Lipworth L Tjonneland A Overvad K et al. (2009). Perfl uorooctanoate and perfl uorooctanesulfonate plasma levels and risk of cance r in the general Danish population. J Natl Cancer Inst 101 605-9 .
26. Fitzgibbons PL Henson DE Hutter RV. (1998). Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. Arch Pathol Lab Med 122 1053-5 .
27. Frame SR McConnell EE. (2003). Review of proliferative lesions of the exocrine pancreas in two chronic studies in rates with ammonium perfl uorooctanoate. DuPont-13788 dated October 16 2003 .
28. Frisbee SJ Brooks AP Jr Maher A Flensborg P Arnold S Fletcher T et al. (2009). The C8 health project: design methods and participants. Environ Health Perspect 117 1873-82 .
29. Giesy JP Kannan K. (2001). Global distribution of perfl uorooctane sulfonate in wildlife. Environ Sci Technol 35 1339-42 .
30. Gilliland FD Mandel JS. (1993). Mortality among employees of a perfl uorooctanoic acid production plant. J Occup Med 35 950-4 .
31. Grice MM Alexander BH Hoff beck R Kampa DM. (2007). Self-reported medical conditions in perfl uorooctanesulfonyl fl uoride manufacturing workers. J Occup Environ Me d 49 722-9 .
32. Han X Nabb DL Russell MH Kennedy GL Rickard RW. (2012). Renal elimination of perfl uorocarboxylates (PFCAs). Chem Res Toxicol 25 35-46 .
33. Hardell E Karrman A van Bavel B Bao J Carlberg M Hardell L. (2014). Case-control study on perfl uorinated alkyl acids (PFAAs) and the risk of prostate cancer. Environ Int 63 35-9 .
34. Hardisty JF Wi llson GA Brown WR McConnell EE Frame SR Gaylor DW et al. (2010). Pathology Working Group review and evaluation of proliferative lesions of mammary gland tissues in female rats fed ammonium perfl uorooctanoate (APFO) in the diet for 2 years. Drug Chem Toxicol 33 131-7 .
35. HCN. (2013). Perfl uorooctanoic Acid and Its Salts-Evaluation of the Carcinogenicity and Genotoxicity. The Hague: Health Council of the Netherlands (HCN) .
36. Hill AB. (1965). The environment and disease: association or causation Proc R Soc Med 58 295-300 .
37. Houde M Martin JW Letcher RJ Solomon KR Muir DC. (2006). Biological monitoring of polyfl uoroalkyl substances: A review. Environ Sci Technol 40 3463-73 .
38. IARC 2001 IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 79. Some Thyrotropic Agents. Lyon France: International Association for Research on Cancer (IARC) Press.
39. Innes KE Wimsatt JH Frisbee S Ducatman AM. (2014). Inverse association of colorectal cancer prevalence to serum levels of perfl uorooctane s ulfonate (PFOS) and perfl uorooctanoate (PFOA) in a large Appalachian population. BMC Cancer 14 45 .
40. Jain RB. (2013). Eff ect of pregnancy on the levels of selected perfl uoroalkyl compounds for females aged 17-39 years: data from National Health and Nutrition Examination Survey 2003-2008. J Toxicol Environ Health A 76 409-21.
41. Jain RB. (2014). Contribution of diet and other factors to the levels of selected polyfl uorinated compounds: data from NHANES 2003- 2008. Int J Hyg Environ Health 217 52-61 .
42. Jurek AM Greenland S Maldonado G Church TR. (2005). Proper interpretation of non-diff erential misclassifi cation eff ects: expectations vs. observations. Int J Epidemiol 34 680-7 .
43. Ju rek AM Greenland S Maldonado G. (2008). How far from nondiff erential does exposure or disease misclassifi cation have to be to bias measures of association away from the null Int J Epidemiol 37 382-5 .
44. Kannan K Corsolini S Falandysz J Fillmann G Kumar KS Loganathan BG et al. (2004). Perfl uorooctanesulfonate and related fl uorochemicals in human blood from several countries. Environ Sci Technol 38 4489-95 .
45. Kato K Wong LY Jia LT Kuklenyik Z Calafat AM. (2011). Trends in exposure to polyfl uoroalkyl chemicals in the U.S. Population: 1999- 2008. Environ Sci Technol 45 8037-45 .
46. Kennedy GL Jr Butenhoff JL Olsen GW O'Connor JC Seacat AM Perkins RG et al. (2004). The toxicology of perfl uorooctanoate. Crit Rev Toxicol 34 351-84 .
47. Klaunig JE Babich MA Baetcke KP Cook JC Corton JC David RM et al. (2003). PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit Rev Toxicol 33 655-780 .
48. Kl aunig JE Hocevar BA Kamendulis LM. (2012). Mode of action analysis of perfl uorooctanoic acid (PFOA) tumorigenicity and human relevance. Reprod Toxicol 33 410-8.
49. Klimstra DS Heff ess CS Oertel JE R osai J. (1992). Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases. Am J Surg Pathol 16 815-37 .
50. La Vecchia C Negri E. (2014). A review of epidemiological data on epilepsy phenobarbital and risk of liver cancer. Eur J Cancer Prev 23 1-7 .
51. Leonard RC Kreckmann KH Sakr CJ Symons JM. (2008). Retrospective cohort mortality study of workers in a polymer productio n plant including a reference population of regional workers. Ann Epidemiol 18 15-22 .
52. Li N Du XL Reitzel LR Xu L Sturgis EM. (2013). Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: review of incidence trends by socioeconomic status within the surveillance epidemiology and end results registry 1980- 2008. Thyroid 23 103-10 .
53. Lim TC Wang B Huan g J Deng S Yu G. (2011). Emission inventory for PFOS in China: review of past methodologies and suggestions. Scientifi cWorldJournal 11 1963-80 .
54. Lissner L Skoog I Andersson K Beckma n N Sundh V Waern M et al. (2003). Participation bias in longitudinal studies: experience from the population study of women in Gothenburg Sweden. Scand J Prim Health Care 21 242-7.
55. Loccisan o AE Campbell Jr. J.L. Butenhoff JL Andersen ME Clewell III H.J.. (2012a). Comparison and evaluation of pharmacokinetics of PFOA and PFOS in the adult rat using a physiologically based pharmacokinetic model. Reprod Toxicol 33 452-67 .
56. Loccisano AE Campbell Jr. J.L. Butenhoff JL A ndersen ME Clewell III H.J.. (2012b). Evaluation of placental and lactational pharmacokinetics of PFOA and PFOS in the pregnant lactating fetal and neonatal rat using a physiologically based pharmacokinetic model. Reprod Toxicol 33 468-90 .
57. Loccisano AE Longnecker MP Campbell Jr. J.L. Andersen ME Clewell III H.J.. (2013). Development of PBPK models for PFOA and PFOS for human pregnancy and lactation life stages. J Toxico l Environ Health A 76 25-57.
58. Lundin JI Alexander BH Olsen GW Church TR. (2009). Ammonium perfl uorooctanoate production and occupational mortality. Epidemiology 20 921-8.
59. Martignoni M Groothuis GM de Kanter R. (2006). Species diff erences between mouse rat dog monkey and human CYP-mediated drug metabolism inhibition and induction. Expert Opin Drug Metab Toxicol 2 875-94 .
60. National Toxicology Program. (1997). NTP toxicology and carcinogenesis studies of tetrafl uoroethylene (CAS No. 116-14-3) in F344 rats and B6C3F1 mice (inhalation studies). Natl Toxicol Program Tech Rep Ser 450 1-321 .
61. Olsen GW Burlew MM Marshall JC Burris JM Mandel JH. (2004). Analysis of episodes of care in a perfl uorooctanesulfonyl fl uoride production facility. J Occup Environ Med 46 837-46 .
62. Olsen GW Burris JM Burlew MM Mandel JH. (2000). Plasma cholecystokinin and hepatic enzymes cholesterol and lipoproteins in ammonium perfl uorooctanoate production workers. Drug Chem Toxicol 23 603-20 .
63. Olsen GW Burris JM Ehresman DJ Froehlich JW Seacat AM Butenhoff JL Zobel LR. (2007). Half-life of serum elimination of perfl uorooctanesulfonate perfl uorohexanesulfo nate and perfl uorooctanoate in retired fl uorochemical production workers. Environ Health Perspect 115 1298-305 .
64. Olsen GW Gilliland FD Burlew MM Burris JM Mandel JS Mandel JH. (199 8). An epidemiologic investigation of reproductive hormones in men with occupational exposure to perfl uorooctanoic acid. J Occup Environ Med 40 614-22 .
65. Olsen GW Lange CC Ellefson ME Mair DC Church TR Goldberg CL et al. (2012). Temporal trends of perfl uoroalkyl concentrations in American Red Cross adult blood donors 2000-2010. Environ Sci Technol 46 6330-8 .
66. Olsen GW Logan PW Hansen KJ Simpson CA Burris JM Burlew MM et al. (2003). An occupational exposure assessment of a perfl uorooctanesulfonyl fl uoride production site: biomonitoring. AIHA J (Fairfax Va) 64 651-9.
67. Olsen GW Zobel LR. (2007). Assessment of lipid hepatic and thyroid parameters with serum perfl uorooctanoate (PFOA) concentrations in fl uorochemical production workers. Int Arch Occup Environ Health 81 231-46 .
68. Pelkonen O Turpeinen M Hakkola J Honkakoski P Hukkanen J Raunio H. (2008). Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 82 667-715.
69. Prevedouros K Cousins IT Buck RC Korzeniowski SH. (2006). Sources fate and transport of perfl uorocarboxylates. Environ Sci Technol 40 32-44 .
70. Richardson LC Neri AJ Tai E Glenn JD. (2012). Testicular cancer: A narrative review of the role of socioeconomic position from risk to survivorship. Urol Oncol 30 95-101 .
71. Sakr CJ Krec kmann KH Green JW Gillies PJ Reynolds JL Leonard RC. (2007). Cross-sectional study of lipids and liver enzymes related to a serum biomarker of exposure (ammonium perfl uorooctanoate or APFO) as part of a general health sur vey in a cohort of occupationally exposed workers. J Occup Environ Med 49 1086-96 .
72. Sarma AV McLaughlin JC Schottenfeld D. (2006). Chapter 60: Testicular cancer. In: Schottenfeld D Fraumeni JF Jr Eds. Cancer Epidemiology and Prevention 3rd edition. New York: Oxford University Press 1151-65 ..
73. Seacat AM Thomford PJ Butenhoff JL. (2002). Terminal observations in Sprague-Dawley rats after lifetime dietary exposure to potassium perfl uorooctanesulfonate [Abstract]. Toxicologist 66 185 .
74. Shin HM Vieira VM Ryan PB Detwiler R Sanders B Steenland K Bartell SM. (2011a). Environmental fate and transport modeling for perfl uorooctanoic acid emitted from the Washington Works Facility in West Virginia. Environ Sci Technol 45 1435-42 .
75. Shin HM Vieira VM Ryan PB Steenl and K Bartell SM. (2011b). Retrospective exposure estimation and predicted versus observed serum perfl uorooctanoic acid concentrations for participants in the C8 Health Project. Environ Health Perspect 119 1760-5.
76. Sibinski LJ. (1987). Two year oral (diet) toxicity/carcinogenicity study of fl uorochemical FC-143 in rats. Experiment No. 0281CR0012. Report prepared for 3M St. Paul Minnesota by Riker Laboratories Inc. U.S. EPA Public Docket AR-226-0437 Washington DC .
77. Sigurdson AJ Doody MM Rao RS Freedman DM Alexander BH Hauptmann M et al. (2003). Cancer incidence in the US radiologic technologists health study 1983-1998. Cancer 97 3080-9 .
78. Steenland K Woskie S. (2012). Cohort mortality study of workers exposed to perfl uorooctanoic acid. Am J Epidemiol 176 909-17 .
79. Sykes G. (1987). Two-year toxicology/carcinogenicity study of fl uorochemical FC-143 in rats. Memo. From G Sykes to C Reinhardt Haskell Lab. Toxicol Ind Med. Dated October 29 1987. As cited in: Draft Risk Assessment of the Potent ial Human Health Eff ects Associated with Exposure to Perfl uorooctanoic Acid and its Salts.
80. U.S. EPA Offi ce of Pollution Prevention and Toxics Risk Assessment Division Washington DC January 4 2005
81. Tan YM Clewell III H.J. Andersen ME. (2008). Time dependencies in perfl uorooctylacids disposition in rat and monkeys: A kinetic analysis. Toxicol Lett 177 38-47 .
82. U.S. EPA. (2006). 2010/2015 PFOA Stewardship Program. Available at: http://www.epa.gov/opptintr/pfoa/pubs/stewardship/. Last updated: January 16 2013.
83. Ubel FA Sorenson SD Roach DE. (1980). Health status of plant workers exposed to fl uorochemicals-A preliminary report. Am Ind Hyg Assoc J 41 584-9 .
84. Vassiliadou I Costopoulou D Ferderigou A Leondiadis L. (2010). Levels of perfl uorooctanesulfonate (PFOS) and perfl uorooctanoate (PFOA) in blood samples from diff erent groups of adults living in Greece. Chemosphere 80 1199-206.
85. Vieira VM Hoff man K Shin HM Weinberg JM Webster TF Fletcher T. (2013). Perfl uorooctanoic acid exposure and cancer outcomes in a contaminated community: A geographic analysis. Environ Health Perspect 121 318-23 .
86. Woskie SR Gore R Steenland K. (2012). Retrospective exposure assessment of perfl uorooctanoic acid serum concentrations at a fl uoropolymer manufacturing plant. Ann Occup Hyg 56 1025-37 .
87. Yeung LW Guruge KS Taniyasu S Yamashita N Angus PW Herath CB. (2013). Profi les of perfl uoroalkyl substances in the liver and serum of patients with liver cancer and cirrhosis in Australia. E cotoxicol Environ Saf 96 139-46.